Sarepta Therapeutics (SRPT) News Today $17.39 -0.52 (-2.90%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$17.37 -0.02 (-0.14%) As of 09/12/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Why Is Sarepta Therapeutics Down Today?Toggle Visibility of Why Is Sarepta Therapeutics Down Today?Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares traded lower amid a flurry of upbeat research notes from Leerink Partners and other brokerages that nonetheless raised earnings forecasts and price targets, suggesting an improving financial outlook despite near-term market pressure. Positive Sentiment: Leerink Partnrs upped Q3 2026 EPS estimates for Sarepta, raising expectations for the company’s third-quarter profitability. Leerink Partnrs Issues Optimistic Forecast for SRPT Earnings Positive Sentiment: Leerink Partnrs issued a positive outlook and boosted earnings estimates for SRPT, reaffirming confidence in the pipeline and growth trajectory. Leerink Partnrs Issues Positive Outlook for SRPT Earnings Positive Sentiment: Leerink Partnrs analysts further raised their near-term EPS projections for SRPT, signaling more robust expected earnings. Leerink Partnrs Analysts Boost Earnings Estimates for SRPT Positive Sentiment: Leerink Partners lifted its price target on SRPT from $12.00 to $15.00 and maintained a market-perform rating, reflecting improved long-term value expectations. Leerink Partners Raises Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $15.00 Positive Sentiment: Brokerages set a consensus price target of $43.50 for SRPT, underscoring significant upside potential from current levels. Brokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target at $43.50 Positive Sentiment: In detailed research notes, Leerink Partnrs raised EPS forecasts across Q3 and Q4 2025, all four quarters of 2026 and full-year FY2025–FY2026, pointing to an improving earnings trajectory. Posted 11h agoAI Generated. May Contain Errors. SRPT Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Leerink Partnrs Issues Optimistic Forecast for SRPT EarningsSeptember 12 at 8:43 AM | marketbeat.comLeerink Partnrs Issues Positive Outlook for SRPT EarningsSeptember 12 at 2:39 AM | americanbankingnews.comLeerink Partnrs Analysts Boost Earnings Estimates for SRPTSeptember 12 at 2:03 AM | americanbankingnews.comLeerink Partners Raises Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $15.00September 11 at 10:39 AM | marketbeat.comBrokerages Set Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Price Target at $43.50September 11 at 2:43 AM | americanbankingnews.com15,163 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by Scientech Research LLCSeptember 10 at 5:42 AM | marketbeat.comLeerink Partners Issues Positive Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock PriceSeptember 10 at 2:22 AM | americanbankingnews.comSarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of "Hold" by AnalystsSeptember 9, 2025 | marketbeat.comEventide Asset Management LLC Lowers Position in Sarepta Therapeutics, Inc. $SRPTSeptember 6, 2025 | marketbeat.comSarepta Therapeutics, Inc. $SRPT Stock Holdings Lifted by EcoR1 Capital LLCSeptember 6, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Shares Up 6.1% - Still a Buy?September 5, 2025 | marketbeat.comSarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2025-2026 Academic YearSeptember 5, 2025 | businesswire.comSarepta Therapeutics, Inc. $SRPT Shares Purchased by 683 Capital Management LLCSeptember 4, 2025 | marketbeat.comADAR1 Capital Management LLC Acquires 82,919 Shares of Sarepta Therapeutics, Inc. $SRPTSeptember 4, 2025 | marketbeat.comSarepta Therapeutics, Inc. $SRPT Shares Sold by Vestal Point Capital LPSeptember 4, 2025 | marketbeat.comPDT Partners LLC Raises Stock Holdings in Sarepta Therapeutics, Inc. $SRPTSeptember 4, 2025 | marketbeat.comSarepta Therapeutics (SRPT) Fell Despite Reporting Good ResultsSeptember 3, 2025 | finance.yahoo.comSarepta Therapeutics, Inc. $SRPT Shares Sold by Braidwell LPSeptember 3, 2025 | marketbeat.comSarepta Therapeutics Restructures Amid ELEVIDYS ChallengesSeptember 1, 2025 | tipranks.comTrexquant Investment LP Makes New $12 Million Investment in Sarepta Therapeutics, Inc. $SRPTAugust 31, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Cooper Co (COO) and Amylyx Pharmaceuticals Inc (AMLX)August 30, 2025 | theglobeandmail.comNorthern Trust Corp Reduces Position in Sarepta Therapeutics, Inc. $SRPTAugust 30, 2025 | marketbeat.comSarepta Therapeutics Completes Convertible Notes ExchangeAugust 29, 2025 | tipranks.comSRPT Stock Alert: Investors with Large Losses Should Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Sarepta Therapeutics, Inc. Class ActionAugust 29, 2025 | globenewswire.comSarepta Therapeutics, Inc. $SRPT Holdings Boosted by Hsbc Holdings PLCAugust 28, 2025 | marketbeat.comRaymond James Financial Inc. Decreases Position in Sarepta Therapeutics, Inc. $SRPTAugust 28, 2025 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ionis Pharmaceuticals (IONS), Akebia Therapeutics (AKBA) and Sarepta Therapeutics (SRPT)August 27, 2025 | theglobeandmail.comHC Wainwright Reaffirms "Sell" Rating for Sarepta Therapeutics (NASDAQ:SRPT)August 27, 2025 | marketbeat.comElanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600August 26, 2025 | finance.yahoo.comUniversity of Wisconsin Foundation Buys Shares of 27,717 Sarepta Therapeutics, Inc. $SRPTAugust 26, 2025 | marketbeat.comLevi & Korsinsky Notifies Sarepta Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SRPTAugust 26, 2025 | theglobeandmail.comInvestors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your Rights – SRPTAugust 25, 2025 | globenewswire.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta TherapeuticsAugust 25, 2025 | tmcnet.comSarepta Therapeutics (SRPT): Assessing Valuation After Lawsuits and FDA Scrutiny Over ELEVIDYS Safety ConcernsAugust 25, 2025 | finance.yahoo.comForecasting The Future: 44 Analyst Projections For Sarepta TherapeuticsAugust 25, 2025 | benzinga.comSAREPTA FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th DeadlineAugust 25, 2025 | globenewswire.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta TherapeuticsAugust 25, 2025 | mms.businesswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPTAugust 25, 2025 | globenewswire.comClass Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Seeking Recovery for Investors - Contact The Gross Law FirmAugust 25, 2025 | prnewswire.comSarepta Therapeutics (SRPT) Rating Update: HC Wainwright & Co. ...August 25, 2025 | gurufocus.comSRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. ...August 25, 2025 | gurufocus.comSRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. ...August 25, 2025 | gurufocus.comSRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPTAugust 25, 2025 | prnewswire.comSRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmAugust 25, 2025 | prnewswire.comSRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitAugust 24, 2025 | globenewswire.comSarepta Therapeutics, Inc. $SRPT Shares Bought by T. Rowe Price Investment Management Inc.August 24, 2025 | marketbeat.comSRPT DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important ...August 24, 2025 | barrons.comSA analyst upgrades/downgrades: XPENG, GOOG, MNSO, SRPTAugust 23, 2025 | msn.comSRPT FINAL DEADLINE ALERT: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline in Securities Class ActionAugust 23, 2025 | globenewswire.comSRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)August 23, 2025 | globenewswire.com Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SRPT Media Mentions By Week SRPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SRPT News Sentiment▼1.130.93▲Average Medical News Sentiment SRPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SRPT Articles This Week▼2060▲SRPT Articles Average Week Get the Latest News and Ratings for SRPT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies CytomX Therapeutics News Today Editas Medicine News Today Abivax News Today Rhythm Pharmaceuticals News Today Axsome Therapeutics News Today Legend Biotech News Today Cytokinetics News Today Avidity Biosciences News Today Nuvalent News Today TG Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SRPT) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SRPT Stock Alerts